| Title: | Excellent Outcome of Allogeneic Hematopoietic Stem Cell Transplantation Using a Conditioning Regimen with Medium-Dose VP-16, Cyclophosphamide and Total-Body Irradiation for Adult Patients with Acute Lymphoblastic Leukemia |
| Authors: | Shigematsu, Akio Browse this author →KAKEN DB |
| Kondo, Takeshi Browse this author →KAKEN DB |
| Yamamoto, Satoshi Browse this author |
| Sugita, Junichi Browse this author →KAKEN DB |
| Onozawa, Masahiro Browse this author →KAKEN DB |
| Kahata, Kaoru Browse this author |
| Endo, Tomoyuki Browse this author |
| Shiratori, Soichi Browse this author |
| Ota, Shuichi Browse this author |
| Obara, Masato Browse this author |
| Wakasa, Kentaro Browse this author |
| Takahata, Mutsumi Browse this author |
| Takeda, Yukari Browse this author |
| Tanaka, Junji Browse this author →KAKEN DB |
| Hashino, Satoshi Browse this author →KAKEN DB |
| Nishio, Mitsufumi Browse this author →KAKEN DB |
| Koike, Takao Browse this author →KAKEN DB |
| Asaka, Masahiro Browse this author →KAKEN DB |
| Imamura, Masahiro Browse this author →KAKEN DB |
| Keywords: | VP-16 |
| Acute lymphoblastic leukemia |
| Adult |
| Hematopoietic stem cell transplantation |
| Conditioning regimen |
| Issue Date: | May-2008 |
| Publisher: | Elsevier |
| Journal Title: | Biology of Blood and Marrow Transplantation |
| Volume: | 14 |
| Issue: | 5 |
| Start Page: | 568 |
| End Page: | 575 |
| Publisher DOI: | 10.1016/j.bbmt.2008.02.018 |
| PMID: | 18410899 |
| Abstract: | We retrospectively evaluated the outcomes of 37 adult patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT) conditioned with medium-dose VP-16 (VP, 30 mg/kg), cyclophosphamide (CY, 120 mg/kg), and fractionated total-body irradiation (TBI, 12 Gy) (medium-dose VP/CY/TBI). The median age of the patients was 26 years. Thirteen patients underwent transplantation from HLA-matched related donors (MRD), 18 patients underwent transplantation from HLA-matched unrelated donors (MUD), and 6 patients underwent transplantation from HLA-mismatched donors (MMD). Thirty-two patients received bone marrow and 4 patients received peripheral blood stem cells. Ten patients were Philadelphia chromosome-positive (Ph+) and 35 patients were in complete remission (CR) at transplantation. All of the patients achieved engraftment, and grade 3 organ toxicity before engraftment occurred in 27 patients. Grade II-III acute graft-versus-host disease (GVHD) and chronic GVHD (cGVHD) occurred in 15 and 18 patients, respectively. No patient developed grade IV acute GVHD (aGVHD) or died of GVHD. At median follow-up of 35.1 months, 32 patients were alive and all Ph+ patients were alive. Three patients died of relapse and 2 died of transplant-related mortality (TRM). The actuarial 3-year overall survival (OS) rate, relapse rate, and TRM rate were 89.2%, 8.1%, and 5.4%, respectively. Non-CR at transplantation, MRD, and no aGVHD were significant adverse prognostic factors for survival. Medium-dose VP/CY/TBI for adult ALL patients was associated with lower relapse rate and no increase in toxicity, resulting in better survival. |
| Rights: | https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/62833 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
